Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03104218
Other study ID # Jean-Sébastien Roy
Secondary ID
Status Completed
Phase N/A
First received February 8, 2017
Last updated September 14, 2017
Start date January 11, 2016
Est. completion date May 31, 2017

Study information

Verified date September 2017
Source Laval University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Transcranial direct current stimulation (tDCS), an electrostimulation technique known to modulate the motor cortex excitability, has been shown to enhance the effects of rehabilitation in populations with neurological injuries. tDCS could similarly be effective in individuals with rotator cuff (RC) tendinopathy, as this pathology is also associated with pain and motor control deficits. For the treatment of RC tendinopathy, sensorimotor training is effective to reduce pain, increase function and enhance motor control of the shoulder. The addition of tDCS during sensorimotor training could enhance motor learning associated with sensorimotor training and thus improve treatment outcome. PURPOSE: To compare, in terms of symptoms, functional limitations and shoulder control, a group receiving a rehabilitation program centered on sensorimotor training combined with tDCS to a group receiving the same rehabilitation program combined with sham tDCS in individuals with RC tendinopathy. METHODS: Forty adults with RC tendinopathy will take part in the 4 evaluation sessions (0, 3, 6, 12 weeks) and a 6-week rehabilitation program. Outcome measures will be symptoms and functional limitations (Disability of the Arm, Shoulder and Hand and the Western Ontario Rotator Cuff index), as well as acromiohumeral distance ([AHD] ultrasonographic measurement at 0° and 60° of elevation arm). The rehabilitation program will include sensorimotor training, strengthening and education. tDCS will be apply during sensorimotor training on the motor cortex contralateral to the side of pain. A 2-way ANOVA will be used to analyse the effects of tDCS on the outcomes.


Description:

Read more »
Read more »

Study Design


Related Conditions & MeSH terms


Intervention

Other:
tDCS group
Interventions: movement training, strengthening, patient education. tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training).40 The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles)57, contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
Placebo group
Interventions: movement training, strengthening, patient education. The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial "itching" sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition.

Locations

Country Name City State
Canada Center of Interdisciplinary Research in Rehabilitation and Social Integration Quebec City Quebec

Sponsors (1)

Lead Sponsor Collaborator
Laval University

Country where clinical trial is conducted

Canada, 

References & Publications (8)

See more »

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Symptoms perceived at week 3,6 and 12. Change from Baseline Symptoms perceived at week 3,6 and 12 with DASH (Disability of the Arm, Shoulder and Hand; self-administered questionnaire) At week 3, 6, and 12, the self-administered DASH questionnaires will be administered.
Primary Change from Functional limitations perceived at week 3,6 and 12. Change from Functional limitations at week 3,6 and 12 with WORC (Western Ontario Rotator Cuff Index; self-administered questionnaire) At week 3, 6, and 12, the self-administered WORC questionnaire will be administered.
Secondary Change from US measurement of supraspinatus tendon at week 0 and 6. US measurement of supraspinatus tendon will be assessed. Supraspinatus tendon measures will be obtained with the transducer perpendicularly, one centimeter behind to the anterolateral aspect of the surface of the acromion. The thickness of the tendon borders will be defined inferiorly as the first hyperechoic region above the anechoic articular cartilage of the humeral head, and the hyperechoic superior border of the tendon before the anechoic subdeltoid bursa. Three measures will be taken, and the mean tendon thickness measured will be expressed as a percentage of the mean AHD at rest using the following formula: occupation ratio = [(tendon thickness/AHD) x 100]. US measurement will be performed at week 0 and 6.
Secondary Change from Corticospinal excitability of the infraspinatus (IS) muscle at day 1 before the first treatment and day 1 after the first treatment. Corticospinal excitability of the infraspinatus (IS) muscle will be acquired using a stimulator. Stimuli will be applied over grid sites spaced 1 cm apart and positioned over the upper limb area of primary motor cortex (M1). Prior to the experiment, subjects will be asked to perform two IS maximal voluntary contractions (MVC). Maximal value over the two trials will be used to compute electromyographic targets during experimental task. Corticospinal excitability will be evaluated during slight voluntary contraction.The optimal location for stimulation of IS will be determined (hotspot), as well as the active motor threshold (aMT) at this site. aMT will be determined as the minimal intensity of stimulation required to elicit motor evoked potential (MEP) larger than 150 µ Volts in at least 6 out of 12 trials at the hotspot for IS at 5% of MVC. Ten stimulations will be performed at the hotspot at 120% of the threshold for IS. Through first tDCS treatment of each participant.
Secondary Change from US measurement of AHD at week 0 and 6. US measurement of AHD will be performed using an ultrasound scanner with a 7.5-12 Mhz linear array probe. The US measurement of AHD is defined as the tangential distance between the hyperechoic bony landmarks of the humeral head and the inferior edge of the acromion visible on the longitudinal sonogram. Measurement obtained represents the AHD at the anterior outlet of the subacromial space. Measurements will be taken in a sitting position with the arm at rest, and at 45° and 60° of active abduction. For each arm position, two measures will be taken, and the mean AHD will be calculated. These measures are highly reliable (ICC > 0.90). US measurement of AHD will be performed at week 0 and 6.
See also
  Status Clinical Trial Phase
Completed NCT05561452 - The Efficacy of PRP Injection in the Treatment of Rotator Cuff Syndrome N/A
Terminated NCT03013192 - Three Month Automated Messaging Intervention N/A
Completed NCT02881021 - Effects of Kinesiotaping on Symptoms, Functional Limitations, and Underlying Deficits of Patients With Rotator Cuff Tendinopathy N/A
Not yet recruiting NCT05969652 - Comparison of the Effectiveness Heavy Slow Resistance and Eccentric Training in Rotator Cuff Tendinopathy N/A
Completed NCT05320419 - The Effect of Amniotic Membrane Injection as An Addition to Physical Therapy in Patients With Rotator Cuff Tear N/A
Completed NCT03454321 - IS'ECHO : Impact of Bursitis on the Efficacy of Subacromial Steroid Injection in Rotator Cuff Tendinopathy
Completed NCT06031857 - Comparison of Kinesio Tape and Dry Needling for the Management of Rotator Cuff Tendinopathy: A Randomized Control Trial N/A
Withdrawn NCT03032432 - A Dynamic Elastic Garment (DEG) in Patients With Rotator Cuff Tendinopathy Phase 4
Completed NCT05207384 - Comparison of Subacromial Ozone (O2-O3) and Corticosteroid Injections in the Treatment of Rotator Cuff Tendinopathy N/A
Completed NCT04766905 - Mini Lateral Shoulder Approach N/A
Active, not recruiting NCT05124769 - PAin During Shoulder Exercise N/A
Completed NCT01915979 - Effect of Plasma Rich in Growth Factors in Rotator Cuff Tendinopathy Phase 3
Not yet recruiting NCT02982460 - Effects of Isoinertial Training on Rotator Cuff Tendinopathy N/A
Active, not recruiting NCT05758415 - Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy Phase 3
Active, not recruiting NCT05722522 - Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy Phase 3
Completed NCT01423682 - The Influence of Eccentric Training on the Volume and Vascularisation of the Rotator Cuff in Patients With Rotator Cuff Tendinopathy and Healthy Subjects N/A